A new synthesis of the GPIIb/IIIa receptor antagonist SB-214857-A

被引：23

作者：

Andrews, IP ^{[1
]}

Atkins, RJ ^{[1
]}

Badham, NF ^{[1
]}

Bellingham, RK ^{[1
]}

Breen, GF ^{[1
]}

Carey, JS ^{[1
]}

Etridge, SK ^{[1
]}

Hayes, JF ^{[1
]}

Hussain, N ^{[1
]}

Morgan, DO ^{[1
]}

Share, AC ^{[1
]}

Smith, SAC ^{[1
]}

Walsgrove, TC ^{[1
]}

Wells, AS ^{[1
]}

机构：

[1] GlaxoSmithKline Pharmaceut, Synthet Chem, Tonbridge TN11 9AN, Kent, England

来源：

TETRAHEDRON LETTERS | 2001年 / 42卷 / 29期

关键词：

asymmetric synthesis; benzodiazepine; carbonylation; enzyme reaction; epimerisation; hydrogenation;

D O I：

10.1016/S0040-4039(01)00843-7

中图分类号：

O62 [有机化学];

学科分类号：

070303 ; 081704 ;

摘要：

A new synthesis of lotrafiban SB-214857-A is reported. The key steps are the preparation of racemic (4-melhyl-3-oxo-2,3,4,5-tetrahydro-1H-benzo[c][1,4]diazepin-2-yl)-acid methyl ester from 2-nitrobenzyl alcohol, a resolution using an immobilised lipase enzyme and a palladium-catalysed aminocarbonylation reaction. (C) 2001 Elsevier Science Ltd. All rights reserved.

引用

页码：4915 / 4917

页数：3

共 50 条

[1] The development of a manufacturing route for the GPIIb/IIIs receptor antagonist SB-214857-A. Part 2: Conversion of the key intermediate SB-235349 to SB-214857-A
Atkins, RJ
Banks, A
Bellingham, RK
Breen, GF
Carey, JS
Etridge, SK
Hayes, JF
Hussain, N
Morgan, DO
Oxley, P
Passey, SC
Walsgrove, TC
Wells, AS
ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2003, 7 (05) : 663 - 675
[2] An alternative synthesis of a potent GPIIb/IIIa receptor antagonist
Hayes, JF
SYNLETT, 1999, : 865 - 866
[3] Enantiospecific synthesis of SB 214857, a potent, orally active, nonpeptide fibrinogen receptor antagonist
Miller, WH
Ku, TW
Ali, FE
Bondinell, WE
Calvo, RR
Davis, LD
Erhard, KF
Hall, LB
Huffman, WF
Keenan, RM
Kwon, C
Newlander, KA
Ross, ST
Samanen, JM
Takata, DT
Yuan, CK
TETRAHEDRON LETTERS, 1995, 36 (52) : 9433 - 9436
[4] SE 214857: A novel nm peptide orally active potent and selective platelet GPIIb/IIIa receptor antagonist: In vitro and in vivo pharmacology
Feuerstein, G
Wong, A
Nichols, A
Samanen, J
Stadel, JM
VaskoMoser, J
Koster, P
Valocik, R
CIRCULATION, 1996, 94 (08) : 3007 - 3007
[5] Monitoring GPIIb-IIIa antagonist receptor blockade
Jennings, LK
White, MM
Longhurst, CM
Cook, GA
Mendoza, MC
THROMBOSIS AND HAEMOSTASIS, 1997, : P2723 - P2723
[6] Evaluation of platelet GPIIb/IIIa receptor bockade by antagonist
Gallo, L.
Lattuada, A.
Russo, U.
Rossi, E.
CYTOMETRY PART A, 2006, 69A (05) : 460 - 460
[7] Design and synthesis of new antagonist peptides for platelet GPIIb/IIIa receptor as anti-thrombotic agents
Hayashi, Y
Sato, Y
Katada, J
Takiguchi, Y
Ojima, I
Uno, I
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1996, 6 (12) : 1351 - 1356
[8] Sibrafiban -: Xubix® -: Platelet antiaggregatory -: gpIIB/IIIA receptor antagonist
不详
DRUGS OF THE FUTURE, 2000, 25 (12) : 1328 - 1328
[9] Orbofiban: An orally active GPIIB/IIIa platelet receptor antagonist
Nicholson, NS
Abood, NA
Panzer-Knodle, SG
Frederick, LG
Page, JD
Salyers, AK
Suleymanov, OD
Szalony, JA
Taite, BB
Anders, RJ
MEDICINAL RESEARCH REVIEWS, 2001, 21 (03) : 211 - 226
[10] Tirofiban hydrochloride -: Aggrastat® -: Platelet antiaggregatory -: GPIIb/IIIa receptor antagonist
不详
DRUGS OF THE FUTURE, 2000, 25 (09) : 995 - 997

← 1 2 3 4 5 →